drugset / Trial / NCT01058174

Liver Transplant European Study Into the Prevention of Fungal Infection

NCT01058174

Phase 3 Completed 350 enrolled Astellas Pharma Inc
RandomizedParallel-groupOpen-labelPrevention

Summary

Prevention of invasive fungal infection in high risk patients following liver transplant.

Timeline

Start
2009-12-15
Primary completion
2012-05-03
Completion
2012-05-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amphotericin B Unknown Intravenous
Comparator Caspofungin Other / unclassified Intravenous
Comparator Fluconazole Small molecule Intravenous
Subject Micafungin Peptide 100 mg Intravenous